These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16038431)

  • 1. [New therapies for inflammatory bowel disease].
    Matsui T
    Nihon Shokakibyo Gakkai Zasshi; 2005 Jul; 102(7):855-65. PubMed ID: 16038431
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in Pediatric Inflammatory Bowel Disease.
    Maxwell EC; Grossman AB
    Adolesc Med State Art Rev; 2016; 27(1):57-74. PubMed ID: 27363233
    [No Abstract]   [Full Text] [Related]  

  • 3. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
    Reenaers C; Belaiche J; Louis E
    Inflamm Bowel Dis; 2010 Aug; 16(8):1271-2. PubMed ID: 20027649
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current status of treatment of inflammatory bowel disease].
    Rodríguez-Moranta F; Soriano-Izquierdo A; Guardiola J
    Cir Esp; 2007 Nov; 82(5):254-9. PubMed ID: 18021623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab to treat severe ulcerative colitis.
    Cury DB; Cury Mde S; Elias GV; Mizsputen SJ
    World J Gastroenterol; 2009 Apr; 15(14):1771-3. PubMed ID: 19360923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
    Eliadou E; Day AS; Thompson-Fawcett MW; Gearry RB; Rowbotham DS; Walmsley R; Schultz M; Inns SJ; ;
    N Z Med J; 2015 Oct; 128(1423):63-76. PubMed ID: 26645757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.
    Farkas K; Molnár T; Szepes Z
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):695-702. PubMed ID: 24738535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab or cyclosporine for severe ulcerative colitis.
    Järnerot G
    Gastroenterology; 2006 Jan; 130(1):286; author reply 287. PubMed ID: 16401502
    [No Abstract]   [Full Text] [Related]  

  • 10. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ; Cominelli F
    Adv Intern Med; 1998; 43():143-74. PubMed ID: 9506181
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab and azathioprine: bridge or parachute?
    Travis S
    Gastroenterology; 2006 Apr; 130(4):1354-7. PubMed ID: 16618428
    [No Abstract]   [Full Text] [Related]  

  • 12. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers.
    Armuzzi A; Pugliese D
    Inflamm Bowel Dis; 2014 Dec; 20(12):E25. PubMed ID: 25397894
    [No Abstract]   [Full Text] [Related]  

  • 14. Poor response to thiopurine in inflammatory bowel disease: how to overcome therapeutic resistance?
    Chouchana L; Roche D; Jian R; Beaune P; Loriot MA
    Clin Chem; 2013 Jul; 59(7):1023-6. PubMed ID: 23813427
    [No Abstract]   [Full Text] [Related]  

  • 15. Managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers: similarities and differences.
    Tursi A
    Inflamm Bowel Dis; 2014 Dec; 20(12):E24-5. PubMed ID: 25374289
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided.
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2013 Oct; 38(8):992. PubMed ID: 24074311
    [No Abstract]   [Full Text] [Related]  

  • 17. What is the importance of infliximab and cyclosporine in the treatment of corticosteroid-refractory severe ulcerative colitis?
    Bengi G; Akpinar H
    Turk J Gastroenterol; 2012; 23 Suppl 2():7-12. PubMed ID: 23576083
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
    Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
    Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided; authors' reply.
    Croft A; Walsh A; Doecke J; Radford-Smith G
    Aliment Pharmacol Ther; 2013 Oct; 38(8):993. PubMed ID: 24074312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.